Observational studyJapanese journal of ophthalmology2026
Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration.
Observational study in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Wide-field choroidal thickness changes after loading-phase anti-VEGF therapy in treatment-naïve neovascular AMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo evaluate structural outcomes, including subretinal fluid (SRF) and fibrovascular pigment epithelial detachment (fvPED) volume changes, after switching from aflibercept 2 mg to faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD). STUDY
designRetrospective, observational study.
methodsPatients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the volumes of SRF and fvPED were analyzed using three-dimensional spectral-domain optical coherence tomography data.
resultsA total of 46 eyes from 46 patients were included. All had been maintained on fixed dosing due to difficulty in extending the injection interval. Patients had received a mean of 25.6 aflibercept 2 mg injections, with a mean interval of 7.5 weeks for the last three injections. Subsequently, three faricimab injections were given at similar intervals (7.6 weeks). BCVA remained unchanged (p = 0.066), while CMT, SRF, and fvPED volumes significantly decreased (p < 0.01). A significant correlation was found between the reductions in SRF and fvPED volumes (p < 0.05).
conclusionsSwitching to faricimab led to favorable structural outcomes in nAMD patients previously treated with aflibercept 2 mg, particularly by reducing SRF and fvPED.
Indexed as
Identifiers
40844677What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.